WO2004087307A1 - Produit a base de chitosane, son procede de preparation, procede de preparation de derives dudit produit a base de chitosane et compositions a base de ceux-ci. - Google Patents

Produit a base de chitosane, son procede de preparation, procede de preparation de derives dudit produit a base de chitosane et compositions a base de ceux-ci. Download PDF

Info

Publication number
WO2004087307A1
WO2004087307A1 PCT/RU2003/000159 RU0300159W WO2004087307A1 WO 2004087307 A1 WO2004087307 A1 WO 2004087307A1 RU 0300159 W RU0300159 W RU 0300159W WO 2004087307 A1 WO2004087307 A1 WO 2004087307A1
Authority
WO
WIPO (PCT)
Prior art keywords
nanοκaπsul
mixture
goodbye
χiτοzana
chτο
Prior art date
Application number
PCT/RU2003/000159
Other languages
English (en)
Russian (ru)
Inventor
Boris Olegovich Maier
Nina Ivanovna Komarova
Original Assignee
Boris Olegovich Maier
Nina Ivanovna Komarova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boris Olegovich Maier, Nina Ivanovna Komarova filed Critical Boris Olegovich Maier
Priority to AU2003271241A priority Critical patent/AU2003271241A1/en
Priority to PCT/RU2003/000159 priority patent/WO2004087307A1/fr
Publication of WO2004087307A1 publication Critical patent/WO2004087307A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm

Definitions

  • the method for the production of derivatives is known to be in the form of a gel for the pharmaceutical industry (811 508212, ⁇ 08 ⁇ 37/08, 05/04/1976).
  • S ⁇ s ⁇ b v ⁇ lyuchae ⁇ ⁇ ig ⁇ vlenie ⁇ as ⁇ v ⁇ a ⁇ i ⁇ zana, removal ne ⁇ as ⁇ v ⁇ ivshi ⁇ sya chas ⁇ its ⁇ i ⁇ zana ⁇ il ⁇ vaniem or tsen ⁇ i ⁇ ugi ⁇ vaniem and ⁇ vedenie m ⁇ di ⁇ i ⁇ atsii ⁇ i ⁇ zana atsili ⁇ uyuschimi agen ⁇ ami in schel ⁇ chny ⁇ usl ⁇ viya ⁇ ⁇ i ⁇ 7,0-9,0 with ⁇ sleduyuschim ⁇ myvaniem g ⁇ v ⁇ g ⁇ ⁇ du ⁇ a, ⁇ y vydelyayu ⁇ as ⁇ isl ⁇ y.
  • acylating agents use unsaturated or saturated anhydrides of dicarboxylic acid, for example, maleic, acid, citric, succinic, acetic acid, and acetic acid.
  • the well-known biologically active components are known, in the case of short-circuiting granules, they have a size of 150 nm or 0.1 - 50 ⁇ m ( ⁇ ⁇ 9100298, 6.11, 11.011, 311, 1011, 311, 1011, 311, 1011, 311, 1011, 311, 1011, 311, 311, 1011, 311 and The method of exposure is to be mixed with the product, added to the mixture, added to the resulting mixture of acid or gas from the distribution system.
  • Izves ⁇ en s ⁇ s ⁇ b ⁇ lucheniya ⁇ lime ⁇ ny ⁇ chas ⁇ its (118 6217901, ⁇ 61 ⁇ 9/127, 17.04.2001) with ⁇ azme ⁇ m 20 - 1000 nm
  • s ⁇ glasn ⁇ ⁇ mu is ⁇ dny ⁇ lime ⁇ in zhid ⁇ m ⁇ as ⁇ v ⁇ e ⁇ e ⁇ emeshivayu ⁇ with li ⁇ idami and ⁇ un ⁇ tsi ⁇ nalnymi g ⁇ u ⁇ ami
  • s ⁇ etsi ⁇ ichnymi ⁇ un ⁇ tsi ⁇ nalnym g ⁇ u ⁇ am ⁇ ganiches ⁇ i ⁇ vesches ⁇ v for vzaim ⁇ deys ⁇ viya with ⁇ ymi and / or diagnosis of particles is created by particles of a polimer.
  • the dispersed phase and the dispersed medium are a simple one and the same, but for stitching they are used Part ⁇ l ⁇ ⁇ lime ⁇ a, na ⁇ dyaschayasya in dis ⁇ e ⁇ sn ⁇ y ⁇ aze, ⁇ gda ⁇ a ⁇ ⁇ lime ⁇ in dis ⁇ e ⁇ si ⁇ nn ⁇ y s ⁇ ede in ⁇ b ⁇ az ⁇ vanii ⁇ du ⁇ a not uchas ⁇ vue ⁇ , ch ⁇ susches ⁇ venn ⁇ snizhae ⁇ vy ⁇ d ⁇ du ⁇ a ⁇ ea ⁇ tsii as nan ⁇ chas ⁇ its ⁇ ⁇ n ⁇ sheniyu ⁇ is ⁇ dn ⁇ g ⁇ ⁇ lime ⁇ a throughout the mass.
  • a well-known known method is that the gels obtained by this method have a relatively low accessory capacity. The method does not allow the generation of gels with a size of particles that are cleared; in nanodiazone.
  • the quality of micelle-forming substances is either active or active, or is inactive, or 100, or 210, or , or Tween 60, or Tween 80, or Lubro ⁇ , or Lubro ⁇ , or any mixture thereof, or a particulate micelle-forming, active substance.
  • ⁇ ⁇ aches ⁇ ve gid ⁇ iln ⁇ g ⁇ ⁇ ganiches ⁇ g ⁇ ⁇ as ⁇ v ⁇ i ⁇ elya is ⁇ lzuyu ⁇ gid ⁇ ilnye ⁇ ganiches ⁇ ie ⁇ as ⁇ v ⁇ i ⁇ eli with ⁇ e ⁇ itsien ⁇ m ⁇ ve ⁇ n ⁇ s ⁇ n ⁇ g ⁇ na ⁇ yazheniya not b ⁇ lee 50 dyne / cm: s ⁇ i ⁇ y, ⁇ e ⁇ ny, a ⁇ ma ⁇ iches ⁇ ie uglev ⁇ d ⁇ dy, e ⁇ i ⁇ y, gal ⁇ id ⁇ izv ⁇ dnye ⁇ edelny ⁇ uglev ⁇ d ⁇ d ⁇ v, ⁇ ed ⁇ ch ⁇ i ⁇ eln ⁇ e ⁇ an ⁇ l, me ⁇ an ⁇ l, iz ⁇ an ⁇ l, atse ⁇ n, atse ⁇ ni ⁇ il, di ⁇ san or i ⁇ any mixture
  • ⁇ Brass As a base agent use hydrated sodium hydroxide or potassium hydroxide, sodium hydroxide or hydrated, or any other chemical mixture.
  • ⁇ ⁇ aches ⁇ ve sshivayuscheg ⁇ agen ⁇ a is ⁇ lzuyu ⁇ saturated or unsaturated ⁇ a ⁇ b ⁇ n ⁇ vye, di ⁇ a ⁇ b ⁇ n ⁇ vye or ⁇ i ⁇ a ⁇ b ⁇ n ⁇ vye ⁇ isl ⁇ y, ⁇ a ⁇ ie ⁇ a ⁇ a ⁇ il ⁇ vuyu, atse ⁇ siyan ⁇ a ⁇ nuyu, gli ⁇ u ⁇ susnuyu, glu ⁇ a ⁇ vuyu, diatse ⁇ ilvinnuyu, digli ⁇ levuyu, i ⁇ a ⁇ n ⁇ vuyu, ⁇ ichnuyu, ⁇ n ⁇ vuyu, lim ⁇ nnuyu, malein ⁇ vuyu, mal ⁇ n ⁇ vuyu, me ⁇ a ⁇ il ⁇ vuyu, me ⁇ ilyan ⁇ a ⁇ nuyu, ⁇ i ⁇ n ⁇ vuyu, salitsil ⁇ vuyu,
  • Drying is carried out by centrifuging, or by autoclaving, or by freezing.
  • Fig. 1 shows the basic scheme for the receipt of a manufactured product.
  • the resulting reactive mixture is dispersed in non-uniform pressure fields, which are obtained with a stirrer with a temperature of 12, an increase of a temperature of 10 °. After dispersion, the reactive mixture lasts about 5 minutes.
  • ⁇ ⁇ ea ⁇ tsi ⁇ nnuyu mixture ⁇ i ⁇ a ⁇ m same dis ⁇ e ⁇ gi ⁇ vanii d ⁇ bavlyayu ⁇ crosslinking agen ⁇ - ⁇ as ⁇ v ⁇ angid ⁇ ida yan ⁇ a ⁇ n ⁇ y ⁇ isl ⁇ y in iz ⁇ an ⁇ le, ⁇ y g ⁇ vya ⁇ za ⁇ anee in ⁇ deln ⁇ m s ⁇ a ⁇ ane for cheg ⁇ in 80 ml iz ⁇ an ⁇ la ⁇ as ⁇ v ⁇ yayu ⁇ 25g yan ⁇ a ⁇ n ⁇ g ⁇ angid ⁇ ida. Dispersion of the reaction mixture takes 3 minutes. With continued dispersion into a reactive mixture
  • reaction mixture 100 ml add 1 molar sodium hydroxide, in the amount of about 1.3 liters. With this, the reaction mixture is reacted and, as a result, it reaches 7.3.
  • the resulting reaction mixture can withstand at a temperature of 30 ° C for 5 hours. Then it removes the resulting plant, which immediately flushes the distilled water to the neutral reaction of the stream and dries it by centrifugation.
  • the size of the capsule is divided by the method of small-angle scattering of X-rays.
  • BASIC PARAMETERS OF THE DISTRIBUTION FUNCTIONS ON THE SIZE OF THE SIZE For example, 2.
  • ⁇ nal ⁇ gichn ⁇ ⁇ ime ⁇ u 1 n ⁇ in ⁇ aches ⁇ ve ⁇ ve ⁇ n ⁇ s ⁇ n ⁇ -a ⁇ ivn ⁇ g ⁇ vesches ⁇ va is ⁇ lzuyu ⁇ lub ⁇ l ⁇ ⁇ liches ⁇ ve to 110 ml, in ⁇ aches ⁇ ve ⁇ ganiches ⁇ g ⁇ ⁇ as ⁇ v ⁇ i ⁇ elya - me ⁇ an ⁇ l ⁇ bschim ⁇ bem ⁇ m 100 ml and s ⁇ s ⁇ ⁇ e ⁇ emeshivaniya ⁇ i dis ⁇ e ⁇ gi ⁇ vanii s ⁇ s ⁇ avlyae ⁇ ⁇ l ⁇ 2000 ⁇ b / min. It receives about 300 g of the neutral product with a capsule size of about 200 nm.
  • Example 4 Analogous to example 1, but as a cross-linking agent, they use a solution of anhydrous acid in an isotropic acid, for which 80% of anhydrous acid Mixing and dispersion is around 2000 rpm. Drying of the product is carried out by the initial centrifugation, and then by freezing. A yield of about 250 g of a neutral neutral product with a capsule size of about 100 nm is obtained.
  • Example 4
  • ⁇ nal ⁇ gichn ⁇ ⁇ ime ⁇ u 1 n ⁇ in ⁇ aches ⁇ ve ⁇ ve ⁇ n ⁇ s ⁇ n ⁇ -a ⁇ ivn ⁇ g ⁇ vesches ⁇ va is ⁇ lzuyu ⁇ ⁇ i ⁇ n ⁇ -114 ⁇ liches ⁇ ve 70 ml, in ⁇ aches ⁇ ve ⁇ ganiches ⁇ g ⁇ ⁇ as ⁇ v ⁇ i ⁇ elya - atse ⁇ n ⁇ bschim ⁇ bem ⁇ m 100 ml and dis ⁇ e ⁇ gi ⁇ vanie ⁇ izv ⁇ dya ⁇ in ul ⁇ azvu ⁇ v ⁇ y bath chas ⁇ y v ⁇ ln ⁇ l ⁇ 30 ⁇ gts and m ⁇ schn ⁇ s ⁇ yu ⁇ l ⁇ 500 ⁇ .
  • a small anhydride is used as a cross-linking agent in the amount of 30 g. 300 g of an industrial compound are obtained. 5.
  • P ⁇ ime ⁇ ⁇ nal ⁇ gichn ⁇ ⁇ ime ⁇ u 1 n ⁇ in ⁇ aches ⁇ ve ⁇ ve ⁇ n ⁇ s ⁇ n ⁇ -a ⁇ ivn ⁇ g ⁇ vesches ⁇ va is ⁇ lzuyu ⁇ ⁇ vin ⁇ liches ⁇ ve 80 in 20 ml, in ⁇ aches ⁇ ve ⁇ ganiches ⁇ g ⁇ ⁇ as ⁇ v ⁇ i ⁇ elya - atse ⁇ n ⁇ bschim ⁇ bem ⁇ m 140 ml, and in ⁇ aches ⁇ ve sshivayuscheg ⁇ agen ⁇ a is ⁇ lzuyu ⁇ a ⁇ il ⁇ vy angid ⁇ id in ⁇ liches ⁇ ve 25 g.
  • Examples 7-9 illustrate the resultant chitosan gel.
  • citric acid in a quantity of 30 ml.
  • Example 10 (illumination of a chitano emulsion is illustrated).
  • ⁇ lucheniya ⁇ i ⁇ zan ⁇ v ⁇ y emulsion 200g bi ⁇ l ⁇ giches ⁇ i a ⁇ ivn ⁇ g ⁇ nan ⁇ a ⁇ suli ⁇ vann ⁇ g ⁇ ⁇ i ⁇ zan ⁇ v ⁇ g ⁇ ⁇ du ⁇ a, ⁇ luchenn ⁇ g ⁇ ⁇ ⁇ ime ⁇ u 1 ⁇ meschayu ⁇ in mi ⁇ se ⁇ , d ⁇ bavlyayu ⁇ Zl dis ⁇ illi ⁇ vann ⁇ y v ⁇ dy, za ⁇ em ⁇ e ⁇ emeshivayu ⁇ in ⁇ echenie 3-5 minutes ⁇ i s ⁇ s ⁇ i 8000 - 12000 ⁇ b / min.
  • the resulting suspension is at a temperature of 80 ° C for 3-5 hours. It produces a chitosan emulsion with a size of 10 capsules of capsules.
  • Examples 11–13 illustrate the biologically active ingredients based on the products, gels, emulsions described above.
  • a commercially available gel uses a commercially available gel having a pH of 4.2 to 6.5, and a dynamic viscosity of 400-5000 cps with a size of 0.1 nm is not required.
  • Example 12 The case for the treatment and treatment of lymphadenitis, wt.%: Cleaned gel - 92.7 mg of protein - 3.0 acid - 4.0 mg of silver -0.3.
  • a commercially available gel uses a commercially available gel having a pH of 4.2 to 6.5, and a dynamic viscosity of 400-5000 cps with a size of 0.1 nm is not required.
  • Emulsion with an inhibitor for the prevention of group infections wt.%: A well-emulsified emulsion with a size of 10 nm absorbed capsule. - 98.0 international - 2.0.
  • the use of a good emulsion + interface allows you to sharply increase the effect of the interface due to the enhancement of its absorption through mucous membrane.
  • Protective gel also results in a protective skin protection, avoiding excessive moisture and / or damage to the environment.
  • the combined use of a pure gel or emulsion and biological active substances is a different type of hazardous activity.
  • compo nents of beneficial metals in a small concentration ensures the healing of the healing and disinfecting agents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention se rapporte à un procédé de préparation de produits à base de chitosane biologiquement actifs et de dérivés de ces derniers, et trouve son application dans la production de préparations cosmétiques, de santé-beauté, et pharmacologiques, d'additifs biologiquement actifs pour aliments et produits alimentaires, et en particulier dans la production de crèmes, de pommades, de gels, d'huiles, d'émulsions, de suspensions, de poudres, de comprimés et de films. L'objectif de l'invention est de préparer un produit à base de chitosane présentant une pénétration transdermique élevée. Pour ce faire, l'on prépare un produit à base de chitosane qui a une réaction à pH neutre, dont les particules de chitosane possèdent une structure souple, et qui se présente sous la forme de nanocapsules souples dotées d'une enveloppe à base de chitosane, la taille des nanocapsules ne dépassant pas 1000 nm et la fonction de distribution maximale en fonction de la taille des nanocapsules étant comprise entre 0,1 et 500 nm. Ledit objectif est également atteint par un procédé de préparation dudit produit à base de chitosane, de ses dérivés sous forme de gels et d'émulsions, et de compositions biologiquement actives à base de ceux-ci.
PCT/RU2003/000159 2003-03-31 2003-03-31 Produit a base de chitosane, son procede de preparation, procede de preparation de derives dudit produit a base de chitosane et compositions a base de ceux-ci. WO2004087307A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003271241A AU2003271241A1 (en) 2003-03-31 2003-03-31 Chitosan product, method for the production thereof, methods for producing chitosan product derivatives and compositions based thereon
PCT/RU2003/000159 WO2004087307A1 (fr) 2003-03-31 2003-03-31 Produit a base de chitosane, son procede de preparation, procede de preparation de derives dudit produit a base de chitosane et compositions a base de ceux-ci.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2003/000159 WO2004087307A1 (fr) 2003-03-31 2003-03-31 Produit a base de chitosane, son procede de preparation, procede de preparation de derives dudit produit a base de chitosane et compositions a base de ceux-ci.

Publications (1)

Publication Number Publication Date
WO2004087307A1 true WO2004087307A1 (fr) 2004-10-14

Family

ID=33129391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2003/000159 WO2004087307A1 (fr) 2003-03-31 2003-03-31 Produit a base de chitosane, son procede de preparation, procede de preparation de derives dudit produit a base de chitosane et compositions a base de ceux-ci.

Country Status (2)

Country Link
AU (1) AU2003271241A1 (fr)
WO (1) WO2004087307A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007018452A2 (fr) * 2005-08-04 2007-02-15 Boris Olegovich Maier Produit a base de chitosane et procede de sa fabrication
CN100415807C (zh) * 2006-03-20 2008-09-03 扬州大学 N-琥珀二酰壳聚糖自组装纳米微粒及制备方法
CN108722358A (zh) * 2017-04-14 2018-11-02 厦门稀土材料研究所 一种酰胺酸功能化壳聚糖吸附材料及其制备方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000298A1 (fr) * 1989-06-30 1991-01-10 Firextra Oy Methode pour la fabrication continue de chitosan microcristallin
US6217901B1 (en) * 1999-05-25 2001-04-17 Alnis, Llc Liposome-assisted synthesis of polymeric nanoparticles
US6228291B1 (en) * 1998-12-17 2001-05-08 Korea Research Institute Of Chemical Company Process for preparing controlled-released chitosan microcapsule
WO2001032751A1 (fr) * 1999-10-29 2001-05-10 Cognis Deutschland Gmbh & Co. Kg Procede de preparation de chitosanes ou de derives de chitosane nanoparticulaires
RU2172325C2 (ru) * 1997-12-18 2001-08-20 Маев Сергей Петрович Способ получения субстанции на основе хитозана для пищевой и фармацевтической промышленности
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000298A1 (fr) * 1989-06-30 1991-01-10 Firextra Oy Methode pour la fabrication continue de chitosan microcristallin
RU2172325C2 (ru) * 1997-12-18 2001-08-20 Маев Сергей Петрович Способ получения субстанции на основе хитозана для пищевой и фармацевтической промышленности
US6228291B1 (en) * 1998-12-17 2001-05-08 Korea Research Institute Of Chemical Company Process for preparing controlled-released chitosan microcapsule
US6217901B1 (en) * 1999-05-25 2001-04-17 Alnis, Llc Liposome-assisted synthesis of polymeric nanoparticles
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
WO2001032751A1 (fr) * 1999-10-29 2001-05-10 Cognis Deutschland Gmbh & Co. Kg Procede de preparation de chitosanes ou de derives de chitosane nanoparticulaires

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007018452A2 (fr) * 2005-08-04 2007-02-15 Boris Olegovich Maier Produit a base de chitosane et procede de sa fabrication
WO2007018452A3 (fr) * 2005-08-04 2007-04-05 Boris Olegovich Maier Produit a base de chitosane et procede de sa fabrication
CN100415807C (zh) * 2006-03-20 2008-09-03 扬州大学 N-琥珀二酰壳聚糖自组装纳米微粒及制备方法
CN108722358A (zh) * 2017-04-14 2018-11-02 厦门稀土材料研究所 一种酰胺酸功能化壳聚糖吸附材料及其制备方法和用途

Also Published As

Publication number Publication date
AU2003271241A1 (en) 2004-10-25

Similar Documents

Publication Publication Date Title
Thandapani et al. Size optimization and in vitro biocompatibility studies of chitosan nanoparticles
EP0267788A2 (fr) Complexe de pullulan et de polyéthylène glycol
US5562924A (en) Polysaccharide wall microcapsules containing primary alcohol functions and compositions containing same
US5071706A (en) Oily, free-flowing, microcapsules
CN1142762C (zh) 化妆或皮肤用粉末及其制法和用途
JP2015529261A (ja) カルボキシ官能化アルテルナン
CA2603139A1 (fr) Polymeres a base d'amines et a base d'imines, leurs utilisations et leur preparation
CN102702539A (zh) 一种多巴胺改性的透明质酸胶束的制备方法
Ioelovich Nanoparticles of amorphous cellulose and their properties
AU726617B2 (en) Cellulose derivatives
JP2003321398A (ja) 多糖類複合体及びその製造方法
WO2004087307A1 (fr) Produit a base de chitosane, son procede de preparation, procede de preparation de derives dudit produit a base de chitosane et compositions a base de ceux-ci.
Goh et al. Microfibrillated cellulose-reinforced alginate microbeads for delivery of palm-based vitamin E: Characterizations and in vitro evaluation
RU2313538C2 (ru) Хитозановый продукт, способ его получения (варианты)
JPH0558881A (ja) ヒアルロン酸ゲル及びその製造方法
CN113616617A (zh) 一种可超声释放no气体的改性白蛋白纳米粒子、其制备方法及应用
CN104229851A (zh) 一种蛋壳超微活性碳酸钙的制备方法
Hassabo et al. Extraction, structural properties, and applications of alginic acid
JPH045489B2 (fr)
KR20040017800A (ko) 키토산을 함유하는 다성분 조성물 및 그의 제조방법
EP0621877A1 (fr) Esters d'acide pectique et pectinique
JPS63210101A (ja) キトサン又はキチン多孔質超微小粒状体の製造方法
Shalaka et al. Vitamin E loaded pectin alginate microspheres for cosmetic application
Lesser Alginates in drugs and cosmetics
JPS61159430A (ja) 再分散懸濁性の良好なキチン又はキトサン組成物の製法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP